External Validation of the NESMS Clinical Prediction Score V.1
Research type
Research Study
Full title
External validation of the New England Spinal Metastatic Score - 12 month survival in patients with Metastatic Spinal Disease.
IRAS ID
302342
Contact name
Shreya Srinivas
Contact email
Sponsor organisation
Sheffield Teaching Hospitals NHS Foundation Trust
Duration of Study in the UK
0 years, 9 months, 19 days
Research summary
The New England Spinal Metastases Score (NESMS) is a new and accessible scoring tool which helps predict survival in patients with spinal metastases. First published in 2015, it was further validated in 2021 with a multicentre, prospective trial. The results of which revealed NESMS to be a reliable tool in predicting 12-month survival rates for patients with spinal metastatic disease within an affluent, metropolitan population in the United States.
This study aims to determine if this same prognostic tool can be reliably applied to patients who present to spinal surgeons within the UK with metastatic spinal disease.
We aim to conduct a retrospective search of patients with metastatic spinal cord compression referred to our spinal surgery service. Demographics analysed will include included gender, age, primary tumour type, albumin levels, ambulatory status and number of co-morbidities to calculate the NESMS score as well as mortality at 3,6 and 12 months.
This will then undergo statistical analysis to assess if the NESMS score reliably predicts 12-month mortality within our population.
REC name
N/A
REC reference
N/A